Topic: RNA therapeutics

Develop RNA-based therapeutics for neurodegenerative disease in the Non-coding Genomics research unit led by Stefano Gustincich. The work combines genomic analysis to identify pharmacological targets with proof-of-concept experiments for RNA medicines. This is a 12-month collaboration contract based in Aosta. The advertised annual gross salary range is EUR 35,000–40,000.

Support in vivo pharmacology for RNA therapeutics by carrying out rodent efficacy studies, dosing and sample collection. The work connects animal experiments with molecular measurements including PCR-based assays, ELISA and western blotting, in collaboration with the discovery team. This is a full-time, on-site position. The advertised base salary range is USD 90,000–110,000. Apply through the employer’s current Lever vacancy; no fixed closing date is stated.

Katalin Karikó and Drew Weissman explain the scientific development of messenger RNA as a therapeutic platform. Their lectures address why laboratory-produced RNA can trigger inflammatory responses and how modification of its nucleosides changes immune recognition and improves protein production. The programme connects those molecular findings with the practical challenges of making RNA stable and delivering it into cells, including lipid-nanoparticle formulations. It follows the development of modified mRNA from a difficult experimental material to a foundation for vaccines and other therapeu